{"schema_version":"secwatch.filing_event.v1","accession":"0001819790-26-000037","form_type":"8-K","ticker":"TARS","cik":"0001819790","company_name":"Tarsus Pharmaceuticals, Inc.","filed_at":"2026-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.996772+00:00","generated_at":"2026-05-14T22:52:01.989259+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Tarsus Q1 XDEMVY sales $145.4M (+85% YoY); net loss narrows to $7.0M","bullets":["XDEMVY net product sales $145.4M vs $78.3M YoY; gross margin 94%.","Reaffirmed FY2026 XDEMVY guidance $670-700M; peak sales potential >$2B.","Net loss $7.0M ($0.16 loss per share) vs $25.1M loss ($0.64) YoY.","License fees $16.7M from $15M China regulatory milestone; cash $388.7M.","Phase 2 Calliope trial started for TP-05 Lyme disease prophylaxis; topline H1 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001819790-26-000037","json":"https://secwatch.observer/filing/0001819790-26-000037.json","markdown":"https://secwatch.observer/filing/0001819790-26-000037.md","text":"https://secwatch.observer/filing/0001819790-26-000037.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819790/000181979026000037/0001819790-26-000037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819790/000181979026000037/tars-20260506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T22:52:01.989259+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"00971625ff66d9ea9a2b4d511bb84b87f7751685","claim":"Tarsus Pharmaceuticals, Inc. reported first quarter ended March 31, 2026 results: revenue $145.4 million, net income $7.0 million, EPS $(0.16). Guidance reaffirmed.","evidence_excerpt":"• Product sales, net: were $145.4 million compared to $78.3 million for the same period in 2025, driven by higher volume and improvements in the gross-to-net discount. • License fees and collaboration revenue: were $16.7 million related to a $15.0 million regulatory milestone achieved under the China Out-License and $1.7 million of required China withholding tax associated with this milestone. The milestone payment was recorded on a gross basis, which increased license fees and collaboration revenue by $1.7 million, with an equal offsetting amount recorded as foreign tax expense within provision for income taxes. There were no license fees and collaboration revenue in the same period in 2025. • Cost of sales: were $9.4 million compared to $5.2 million for the same period in 2025, due to manufacturing costs related to XDEMVY, the royalty Tarsus pays on net product sales, and amortization expense for the milestone payments made to our licensor, which is being amortized over its remaining","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979026000037/0001819790-26-000037-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001104659-26-069227","ticker":"YSWY","company_name":"Yesway, Inc.","filed_at":"2026-06-02T11:35:47+00:00","headline":"Yesway reports Q1 net income $30.2M, Adjusted EBITDA $59.2M; introduces FY2026 outlook","event_type":"earnings","sec_items":["2.02","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-069227","json":"https://secwatch.observer/filing/0001104659-26-069227.json","markdown":"https://secwatch.observer/filing/0001104659-26-069227.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1859836/000110465926069227/0001104659-26-069227-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1859836/000110465926069227/tm2616553d1_8k.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"• Product sales, net: were $145.4 million compared to $78.3 million for the same period in 2025, driven by higher volume and improvements in the gross-to-net discount.\n• License fees and collaboration revenue: were $16.7 million related to a $15.0 million regulatory milestone achieved under the China Out-License and $1.7 million of required China withholding tax associated with this milestone. The milestone payment was recorded on a gross basis, which increased license fees and collaboration revenue by $1.7 million, with an equal offsetting amount recorded as foreign tax expense within provision for income taxes. There were no license fees and collaboration revenue in the same period in 2025.\n• Cost of sales: were $9.4 million compared to $5.2 million for the same period in 2025, due to manufacturing costs related to XDEMVY, the royalty Tarsus pays on net product sales, and amortization expense for the milestone payments made to our licensor, which is being amortized over its remaining","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979026000037/0001819790-26-000037-index.htm","comparable_excerpt":"On June 2, 2026, Yesway, Inc. issued a press release announcing its financial results for the three months ended March 31, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1859836/000110465926069227/0001104659-26-069227-index.htm"}},{"accession":"0001856437-26-000011","ticker":"VSCO","company_name":"Victoria's Secret & Co.","filed_at":"2026-06-02T11:01:54+00:00","headline":"Victoria's Secret Q1 sales up 15% to $1.56B, beats guidance; raises FY2026 outlook","event_type":"earnings","sec_items":["2.02","7.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001856437-26-000011","json":"https://secwatch.observer/filing/0001856437-26-000011.json","markdown":"https://secwatch.observer/filing/0001856437-26-000011.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1856437/000185643726000011/0001856437-26-000011-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1856437/000185643726000011/vsco-20260602.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"• Product sales, net: were $145.4 million compared to $78.3 million for the same period in 2025, driven by higher volume and improvements in the gross-to-net discount.\n• License fees and collaboration revenue: were $16.7 million related to a $15.0 million regulatory milestone achieved under the China Out-License and $1.7 million of required China withholding tax associated with this milestone. The milestone payment was recorded on a gross basis, which increased license fees and collaboration revenue by $1.7 million, with an equal offsetting amount recorded as foreign tax expense within provision for income taxes. There were no license fees and collaboration revenue in the same period in 2025.\n• Cost of sales: were $9.4 million compared to $5.2 million for the same period in 2025, due to manufacturing costs related to XDEMVY, the royalty Tarsus pays on net product sales, and amortization expense for the milestone payments made to our licensor, which is being amortized over its remaining","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979026000037/0001819790-26-000037-index.htm","comparable_excerpt":"The Company reported net sales of $1.560 billion for the first quarter of 2026, an increase of 15% compared to net sales of $1.353 billion for the first quarter of 2025 and above the previously communicated guidance range of $1.490 billion to $1.525 billion. Total comparable sales for the first quarter of 2026 increased 13%. The Company reported operating income for the first quarter of 2026 of $76 million compared to operating income of $20 million in the first quarter of 2025. Net income was $48 million, or $0.56 per diluted share, for the first quarter of 2026 compared to net loss of $2 million, or $0.02 per diluted share, for the first quarter of 2025.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1856437/000185643726000011/0001856437-26-000011-index.htm"}},{"accession":"0001104659-26-069202","ticker":"CTRN","company_name":"Citi Trends Inc","filed_at":"2026-06-02T10:58:00+00:00","headline":"Citi Trends Q1 sales up 14.4% to $230.9M; adjusted EBITDA doubles to $13.9M","event_type":"earnings","sec_items":["2.02","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-069202","json":"https://secwatch.observer/filing/0001104659-26-069202.json","markdown":"https://secwatch.observer/filing/0001104659-26-069202.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1318484/000110465926069202/0001104659-26-069202-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1318484/000110465926069202/tm2616574d1_8k.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"• Product sales, net: were $145.4 million compared to $78.3 million for the same period in 2025, driven by higher volume and improvements in the gross-to-net discount.\n• License fees and collaboration revenue: were $16.7 million related to a $15.0 million regulatory milestone achieved under the China Out-License and $1.7 million of required China withholding tax associated with this milestone. The milestone payment was recorded on a gross basis, which increased license fees and collaboration revenue by $1.7 million, with an equal offsetting amount recorded as foreign tax expense within provision for income taxes. There were no license fees and collaboration revenue in the same period in 2025.\n• Cost of sales: were $9.4 million compared to $5.2 million for the same period in 2025, due to manufacturing costs related to XDEMVY, the royalty Tarsus pays on net product sales, and amortization expense for the milestone payments made to our licensor, which is being amortized over its remaining","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979026000037/0001819790-26-000037-index.htm","comparable_excerpt":"(EXHIBIT 99.1) ---\n\nEX-99.1 2 tm2616574d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 CITITRENDS ANNOUNCES FIRST QUARTER\nFISCAL 2026 RESULTS Q1 2026 total sales increased 14.4% to $230.9 million Comparable store sales growth\nof 13.9%; Two-year stack of 23.8% Q1 2026 Net Income of $7.8 million;\nQ1 2026 adjusted EBITDA* of $13.9 million, more than double Q1 2025 results","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1318484/000110465926069202/0001104659-26-069202-index.htm"}},{"accession":"0000832988-26-000158","ticker":"SIG","company_name":"SIGNET JEWELERS LTD","filed_at":"2026-06-02T10:54:29+00:00","headline":"Signet Q1 sales $1.6B, SSS +1.8%; raises FY27 adjusted EPS guidance","event_type":"earnings","sec_items":["2.02","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000832988-26-000158","json":"https://secwatch.observer/filing/0000832988-26-000158.json","markdown":"https://secwatch.observer/filing/0000832988-26-000158.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/832988/000083298826000158/0000832988-26-000158-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/832988/000083298826000158/sig-20260602.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"• Product sales, net: were $145.4 million compared to $78.3 million for the same period in 2025, driven by higher volume and improvements in the gross-to-net discount.\n• License fees and collaboration revenue: were $16.7 million related to a $15.0 million regulatory milestone achieved under the China Out-License and $1.7 million of required China withholding tax associated with this milestone. The milestone payment was recorded on a gross basis, which increased license fees and collaboration revenue by $1.7 million, with an equal offsetting amount recorded as foreign tax expense within provision for income taxes. There were no license fees and collaboration revenue in the same period in 2025.\n• Cost of sales: were $9.4 million compared to $5.2 million for the same period in 2025, due to manufacturing costs related to XDEMVY, the royalty Tarsus pays on net product sales, and amortization expense for the milestone payments made to our licensor, which is being amortized over its remaining","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979026000037/0001819790-26-000037-index.htm","comparable_excerpt":"On June 2, 2026, Signet Jewelers Limited (the \"Company\") issued a press release announcing results for the first quarter ended May 2, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/832988/000083298826000158/0000832988-26-000158-index.htm"}},{"accession":"0001104659-26-069198","ticker":"DG","company_name":"DOLLAR GENERAL CORP","filed_at":"2026-06-02T10:54:17+00:00","headline":"Dollar General Q1 EPS $2.00 beats expectations; raises FY2026 EPS guidance","event_type":"earnings","sec_items":["2.02","5.07","7.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-069198","json":"https://secwatch.observer/filing/0001104659-26-069198.json","markdown":"https://secwatch.observer/filing/0001104659-26-069198.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/29534/000110465926069198/0001104659-26-069198-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/29534/000110465926069198/tm2616084d1_8k.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"• Product sales, net: were $145.4 million compared to $78.3 million for the same period in 2025, driven by higher volume and improvements in the gross-to-net discount.\n• License fees and collaboration revenue: were $16.7 million related to a $15.0 million regulatory milestone achieved under the China Out-License and $1.7 million of required China withholding tax associated with this milestone. The milestone payment was recorded on a gross basis, which increased license fees and collaboration revenue by $1.7 million, with an equal offsetting amount recorded as foreign tax expense within provision for income taxes. There were no license fees and collaboration revenue in the same period in 2025.\n• Cost of sales: were $9.4 million compared to $5.2 million for the same period in 2025, due to manufacturing costs related to XDEMVY, the royalty Tarsus pays on net product sales, and amortization expense for the milestone payments made to our licensor, which is being amortized over its remaining","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979026000037/0001819790-26-000037-index.htm","comparable_excerpt":"(NYSE: DG) today reported financial results for its first quarter (13 weeks) ended May 1, 2026. First Quarter Fiscal Year 2026\nHighlights · Net\n Sales Increased 3.4% to $10.8 Billion · Same-Store\n Sales Increased 2.0% · Operating\n Profit Increased 10.8% to $638.5 Million · Diluted\n Earnings Per Share (“EPS”) Increased 12.4% to $2.00 · Cash\n Flow From","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/29534/000110465926069198/0001104659-26-069198-index.htm"}},{"accession":"0001062993-26-002965","ticker":"HIVE","company_name":"HIVE Digital Technologies Ltd.","filed_at":"2026-06-02T10:23:19+00:00","headline":"HIVE FY2026 revenue $297.8M (+158% YoY); GAAP net loss $148.4M","event_type":"earnings","sec_items":["2.02","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001062993-26-002965","json":"https://secwatch.observer/filing/0001062993-26-002965.json","markdown":"https://secwatch.observer/filing/0001062993-26-002965.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720424/000106299326002965/0001062993-26-002965-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720424/000106299326002965/form8k.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"• Product sales, net: were $145.4 million compared to $78.3 million for the same period in 2025, driven by higher volume and improvements in the gross-to-net discount.\n• License fees and collaboration revenue: were $16.7 million related to a $15.0 million regulatory milestone achieved under the China Out-License and $1.7 million of required China withholding tax associated with this milestone. The milestone payment was recorded on a gross basis, which increased license fees and collaboration revenue by $1.7 million, with an equal offsetting amount recorded as foreign tax expense within provision for income taxes. There were no license fees and collaboration revenue in the same period in 2025.\n• Cost of sales: were $9.4 million compared to $5.2 million for the same period in 2025, due to manufacturing costs related to XDEMVY, the royalty Tarsus pays on net product sales, and amortization expense for the milestone payments made to our licensor, which is being amortized over its remaining","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979026000037/0001819790-26-000037-index.htm","comparable_excerpt":"EXHIBIT 99.1 HIVE Digital Technologies Ltd.: Exhibit 99.1 - Filed by newsfilecorp.com Exhibit 99.1 HIVE DIGITAL TECHNOLOGIES LTD. HIVE Achieves FY2026 Total Revenue of $297.8 Million (+158% YoY), HIVE's BUZZ HPC Positioned for Growth This news release constitutes a \"designated news release\" for the purposes of the Company's prospectus supplement dated","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1720424/000106299326002965/0001062993-26-002965-index.htm"}},{"accession":"0000029644-26-000049","ticker":"DCI","company_name":"DONALDSON Co INC","filed_at":"2026-06-01T21:41:36+00:00","headline":"Donaldson Q3 FY2026 sales $995.1M (+5.8%), adj. EPS $1.06 (+7.1%)","event_type":"earnings","sec_items":["2.02","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000029644-26-000049","json":"https://secwatch.observer/filing/0000029644-26-000049.json","markdown":"https://secwatch.observer/filing/0000029644-26-000049.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/29644/000002964426000049/0000029644-26-000049-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/29644/000002964426000049/dci-20260602.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"• Product sales, net: were $145.4 million compared to $78.3 million for the same period in 2025, driven by higher volume and improvements in the gross-to-net discount.\n• License fees and collaboration revenue: were $16.7 million related to a $15.0 million regulatory milestone achieved under the China Out-License and $1.7 million of required China withholding tax associated with this milestone. The milestone payment was recorded on a gross basis, which increased license fees and collaboration revenue by $1.7 million, with an equal offsetting amount recorded as foreign tax expense within provision for income taxes. There were no license fees and collaboration revenue in the same period in 2025.\n• Cost of sales: were $9.4 million compared to $5.2 million for the same period in 2025, due to manufacturing costs related to XDEMVY, the royalty Tarsus pays on net product sales, and amortization expense for the milestone payments made to our licensor, which is being amortized over its remaining","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979026000037/0001819790-26-000037-index.htm","comparable_excerpt":"press release is furnished herewith as Exhibit 99.1. \n\n--- EX-99.1 (EX-99.1) ---\n\nDonaldson Reports Record Third Quarter Fiscal 2026 Sales and Earnings Third quarter sales of $995.1 million, up 5.8% Operating margin of 15.6%; All-time high adjusted operating margin of 16.6% GAAP EPS of $1.00; Adjusted EPS of $1.06, up 7.1% Closed margin-accretive Facet acquisition,","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/29644/000002964426000049/0000029644-26-000049-index.htm"}},{"accession":"0001104659-26-068983","ticker":"GMRS","company_name":"GMR Solutions Inc.","filed_at":"2026-06-01T20:45:55+00:00","headline":"GMR Solutions Q1 revenue $1.46B (+6.6% YoY), net income $106M (+180% YoY), guides FY26 rev $5.9-6.2B","event_type":"earnings","sec_items":["2.02","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-068983","json":"https://secwatch.observer/filing/0001104659-26-068983.json","markdown":"https://secwatch.observer/filing/0001104659-26-068983.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1898718/000110465926068983/0001104659-26-068983-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1898718/000110465926068983/gmrs-20260601x8k.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"• Product sales, net: were $145.4 million compared to $78.3 million for the same period in 2025, driven by higher volume and improvements in the gross-to-net discount.\n• License fees and collaboration revenue: were $16.7 million related to a $15.0 million regulatory milestone achieved under the China Out-License and $1.7 million of required China withholding tax associated with this milestone. The milestone payment was recorded on a gross basis, which increased license fees and collaboration revenue by $1.7 million, with an equal offsetting amount recorded as foreign tax expense within provision for income taxes. There were no license fees and collaboration revenue in the same period in 2025.\n• Cost of sales: were $9.4 million compared to $5.2 million for the same period in 2025, due to manufacturing costs related to XDEMVY, the royalty Tarsus pays on net product sales, and amortization expense for the milestone payments made to our licensor, which is being amortized over its remaining","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979026000037/0001819790-26-000037-index.htm","comparable_excerpt":"today announced financial results for the first quarter ended March 31, 2026, and full year 2026 financial guidance. First Quarter 2026 Financial Highlights ● Net revenue of $1,457.6 million, up 6.6% compared to $1,367.4 million in the first quarter of 2025 ● Net income of $106.3 million, up 179.7% compared to $38.0 million in the first quarter of 2025 ● Adjusted","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1898718/000110465926068983/0001104659-26-068983-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}